Clinical Trial Update: Pivotal Study of N-acetyl-L-leucine for CACNA1A [Phase 3]

View source ↗

Summary

An update on a pivotal Phase 3 trial of N-acetyl-L-leucine for CACNA1A-related disorders, noting that the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Episodic Ataxia Type
• Familial Hemiplegic Migraine Type
• Spinocerebellar Ataxia Type

Drugs mentioned

• N-Acetyl-L-Leucine (N-acetyl-L-leucine)

Snippet

Sponsor: IntraBio Inc | Conditions: CACNA1A, Spinocerebellar Ataxia Type 6 | Phase 3 | Status: NOT_YET_RECRUITING